Sonrotoclax plus azacitidine demonstrates broad antileukemic activity across ELN 2024 genetic risk groups in treatment-naive acute myeloid leukemia unfit for intensive chemotherapy

ASH 2026 • AML • Sonrotoclax • Oral

Guru Subramanian Guru Murthy, MD MS

DISCLAIMER

The contents of the presentation are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and/or efficacy for such investigational products or uses may be made.

SUMMARY

This ongoing phase 1b/2 study evaluated investigational sonrotoclax plus azacitidine in patients with treatment-naïve (TN) acute myeloid leukemia (AML) considered unfit for intensive chemotherapy. This analysis reported the safety and efficacy results of the study across European LeukemiaNet (ELN) 2024 risk groups. As of May 1, 2026, 95 patients with TN unfit AML were treated (74% de novo; 26% secondary). At a median follow-up of 11.5 (range, 0.3-59.0) months, 88% of patients discontinued treatment, and 12% remained on therapy. Grade ≥3 treatment-emergent adverse events (TEAEs) occurred in nearly all patients (99%); most commonly, neutropenia (46%), febrile neutropenia (43%), decreased neutrophil count (42%), anemia (39%), thrombocytopenia (38%), decreased platelet count (34%), and pneumonia (20%) were reported. Grade 5 TEAEs occurred in 12% of patients, most frequently due to infections and infestations (6%). Tumor lysis syndrome was observed in 4 patients (2 clinical) and resolved without sequelae. Overall, 55% of patients achieved complete remission (CR) and 68% achieved CR or CR with incomplete hematologic recovery (CR/CRi); 87% of CR patients achieved CR by the end of cycle 4, with median times to CR and CR/CRi of 1.9 and 1.3 months, respectively. Across ELN 2024 genetic risk groups, CR rates ranged from 40% to 67%, while CR/CRi rates ranged from 60% to 82%. Median duration of response was 21.2 months (95% CI, 7.5-not estimable [NE]; favorable), 6.9 months (95% CI, 2.4-8.7; intermediate), and 12.8 months (95% CI, 6.3-NE; adverse). Measurable residual disease negativity (<10⁻³) among CR patients was 46%-50% across risk groups by the end of cycle 7.

ClinicalTrials.gov ID: NCT04771130

You are now leaving the website

This link is provided for information purposes only. You’ll be leaving beonemedaffairs.com and accessing a third-party website over which [BeOne Medicines | GmbH] has no control or influence.

This link will take you to a third-party website outside of beonemedaffairs.com.

[BeOne Medicines | GmbH] has no control over this website and makes no representations regarding its content or availability in your location. [BeOne Medicines | GmbH] declines any responsibility for third-party information, data usage policies, or personal data processing.

By proceeding, you acknowledge that you are part of the intended audience of the third-party website and confirm your compliance with applicable laws.

Do you want to leave beonemedaffairs.com

You are now leaving the website beonemedaffairs.com and entering another BeOne website with different terms of use. Information included on this website may not be specific to your country. Click Continue to proceed